Being a member of the academic elite doesn’t necessarily make a good doctor, an AusDoc survey has revealed. From an experienced doctor’s perspective, high-achieving academics can face problems in practice. “Almost only the academic elite enter the system. This doesn’t necessarily make the best doctors…they are not used to failure and uncertainty and the hospital,
COVID-19 changed GP engagement permanently. A leading modelling expert explains why digital GTM channels are now essential for pharma companies wanting to reach Australian doctors.
GP registrars carry enormous responsibility with limited experience. AusDoc research reveals 5 practical ways pharma can support registrar confidence and build early HCP relationships.
AusDoc research reveals what Australian GPs actually want from pharma — 6 priority messages that cut through information overload and drive meaningful HCP engagement.
Survey uncovers what medical students need and how best to connect with them Helping medical students to succeed in their studies is a key factor in getting their attention, a recent ADG survey* has found. The survey, conducted in February 2021, asked students in their final two years of study about the tensions they face and what they need
With the sudden and dramatic impact of COVID-19, a survey of GPs and their contact with pharmaceutical field staff during the pandemic reveals a massive drop in face-to-face engagement. The joint Australian Doctor Group and Medicines Australia poll was sent out in mid-May and attracted almost 400 responders. It shows prior to the pandemic half
As Australia enters a new phase of its COVID-19 journey, governments have an increasing opportunity to engage in a two-way conversation with GPs; not only about the virus itself but also about ensuring their patients don’t ignore their general health during the pandemic. GPs are generally satisfied with the COVID-19 information they have received up to now, according to a survey of AusDoc.PLUS readers1. But a big gripe is that different information sources
To download a PDF version of this infographic, please click here.
During COVID-19, pharma’s role extended far beyond new treatments. How the industry’s broader support for Australian GPs reshaped trust and transformed HCP engagement models.
COVID-19 accelerated telehealth adoption across Australian general practice almost overnight. Explore what this shift means for pharma engagement and digital HCP marketing strategy.
Great pharma content marketing starts with great journalism. 10 reasons why working with editorial professionals produces HCP content that builds trust and drives doctor engagement.
A healthy pipeline feeds a changing treatment landscape A record number of oncology drugs was launched in 2018 with a global report recording 15 new cancer drugs for 17 indications last year. In fact, over the past five years oncology treatments appear to have taken centre stage for the pharmaceutical industry. Some 57 oncology therapies for 89
